Kohtaro Toyama

Fujioka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Disappearance of del (7q) with lenalidomide in myelofibrosis complicated with multiple myeloma

Disappearance of del (7q) with lenalidomide in myelofibrosis complicated with multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

Journal: British journal of haematology

Published: February 21, 2026

Composite lymphoma comprising adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive primary central nervous system lymphoma.

Composite lymphoma comprising adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive primary central nervous system lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: January 28, 2026

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Journal: Annals of hematology

Published: January 13, 2026

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Journal: International journal of hematology

Published: July 14, 2025

Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.

Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.

Journal: International journal of hematology

Published: June 06, 2025

CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.

CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.

Journal: International journal of hematology

Published: March 05, 2025

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Journal: Hematological oncology

Published: August 27, 2024

Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).

Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).

Journal: International journal of hematology

Published: September 13, 2023

Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.

Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: March 29, 2023

Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Journal: International journal of hematology

Published: January 28, 2023

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.

Journal: Cancer science

Published: December 14, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026